Table 1.
Patient characteristics
| Variable | Number of Patients (%) n=307 |
|---|---|
| Age, years | |
| Median (range) | 60 (25-88) |
| Histology | |
| Serous | 245 (80%) |
| Others | 62 (20%) |
| Tumor grade | |
| High | 264 (86%) |
| Other | 43 (14%) |
| Preoperative CA-125, U/ml; Median (range) | |
| All patients (n=307) | 840 (40-38100) |
| Optimally debulked (n=209) | 613 (40-29100) |
| Suboptimally debulked (n=98) | 1258 (69-38100) |
| Ascites volume, ml | |
| Median (range) | 900 (0-12000) |
| Residual tumor size | |
| Microscopic optimal | 59 (19%) |
| Macroscopic optimal | 150 (49%) |
| Suboptimal (>1.0 cm) | 98 (32%) |
| Postoperative CA-125, U/ml; Median (range) | |
| All patients (n=307) | 225 (9-29600) |
| Optimally debulked (n=209) | 161(9-8600) |
| Suboptimally debulked (n=98) | 443 (25-29600) |
| Postoperative chemotherapy | |
| IV platinum plus taxane | 251 (82%) |
| IV platinum plus other | 31 (10%) |
| IP platinum plus taxane | 24 (8%) |
| Number of cycles | |
| Median (range) | 6 (1-12) |
| Second-look surgery | |
| Yes | 150 (49%) |
| No | 152 (50%) |
| Missing | 5 (2%) |
| Consolidation chemotherapy | |
| Yes | 143 (47%) |
| No | 161 (52%) |
| Missing | 3 (1%) |
| Perioperative CA-125 response | |
| Steep (≥80%) | 98 (32%) |
| Moderate-High (50-79.99%) | 110 (36%) |
| Moderate-Low (0-49.99%) | 64 (21%) |
| Increase | 35 (11%) |
IV, intravenous; IP, intraperitoneal